Nasdaq:US$9.23 (+0.47) | HKEX:HK$14.28 (+0.70) | AIM:£1.58 (+0.06)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors